Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) Sees Large Growth in Short Interest

Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) was the target of a large increase in short interest during the month of January. As of January 31st, there was short interest totalling 18,600 shares, an increase of 7.5% from the January 15th total of 17,300 shares. Based on an average daily volume of 11,200 shares, the short-interest ratio is presently 1.7 days. Approximately 0.2% of the shares of the stock are short sold.

Armata Pharmaceuticals Stock Down 1.0 %

Shares of NYSEAMERICAN ARMP traded down $0.02 during trading on Tuesday, hitting $1.93. 27,829 shares of the company were exchanged, compared to its average volume of 9,878. The firm has a market cap of $69.83 million, a PE ratio of -1.18 and a beta of 0.87. Armata Pharmaceuticals has a 12-month low of $1.80 and a 12-month high of $4.48.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $7.00 price target on shares of Armata Pharmaceuticals in a report on Thursday, December 19th.

About Armata Pharmaceuticals

Armata Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia.